CANCERS BRONCHIQUES NON A PETITES CELLULES DE STADE AVANCE : CHIMIOTHÉRAPIE
|
|
|
Référence |
Méthodologie |
Critère de jugement |
Nombre d |
Nombre de patients |
Résultat |
|
Identification d |
|||||
|
Donnadieu, 1991 (1) |
MARSL |
Taux de réponse |
100 |
6235 |
En faveur cisplatine,
vindésine, vinblastine, ifosfamide & mitomycine |
|
Rôle de l |
|||||
|
Sculier, 2001 (2) |
MARSL |
Survie globale |
10 |
1769 |
NS HR = 0,95 (IC 95% 0,83 – 1,10) |
|
Rôle de la chimiothérapie avec de la gemcitabine
par rapport à d |
|||||
|
Le Chevalier, 2005 (3) I |
MAI |
Survie |
13 |
4556 |
S HR = 0,90 (0,84 – 0,96) |
|
Cisplatine + docétaxel versus autres associations
avec cisplatine |
|||||
|
Sanchez Lerma, 2004 (4) |
MAI |
Mortalité globale |
3 |
1980 |
NS |
|
Douillard, 2007 (5) I |
MAI |
Survie globale |
8 |
2967 |
S HR = 0,89 (0,82 – 0,96) |
|
Platine + gemcitabine ou vinorelbine |
|||||
|
Gao, 2009 (6) |
MARSL |
Survie à 1 an |
9 |
2186 |
NS HR = 1,06 (0,96 – 1,18) |
|
Cisplatine versus carboplatine |
|||||
|
Hotta, 2004 (7) |
MARSL |
Survie globale |
8 |
2903 |
NS HR = 0,87 (0,80 – 0,94) |
|
Ardizzoni, 2007 (8) |
MADI |
Survie globale |
9 |
2968 |
NS HR = 1,07 (0,99 -1,15) |
|
Jiang, 2007 (9) |
MAI |
Survie globale |
18 |
6906 |
NS RR = 1,00 (0,94 -1,07) |
|
Addition d |
|||||
|
Hotta, 2004 (10) |
MARSL |
Survie globale |
8 |
2374 |
S HR = 0,87 (0,80 -0,94) |
|
Rajeswaran, 2008 (11) |
MARSL |
Survie à 1 an |
17 |
4920 |
S RR = 1,08 (1,014 -1,16) |
|
Chimiothérapie avec ou sans dérivé du platine |
|||||
|
D 2005 (12) |
MAI |
Survie à 1 an |
30 |
6504 |
S (en faveur platine) OR = 1,21 (1,09 – 1,35) |
|
Pujol, 2006 (13) |
MAI |
Risque de décès à 1 an |
11 |
4602 |
S (en faveur platine) OR = 0,88 (0,78 -0,99) |
|
Monochimiothérapie versus polychimiothérapie |
|||||
|
Marino, 1995 (14) |
MARSL |
Risque de mortalité |
9 |
1493 |
S OR = 0,8 (0,6 – 1,0) |
|
Lilenbaum, 1998 (15) |
MAI |
Survie à 6 et 12 mois |
25 |
5156 |
S RR = 1,10 (1,02 – 1,19) et 1,22
(1,03 – 1,45) |
|
Un versus deux agents chimiothérapiques |
|||||
|
Delbaldo, 2004 (16) |
MAI |
Survie médiane |
30 |
6022 |
S OR = 0,80 (0,70 – 0,91) |
|
Deux versus trois agents chimiothérapiques |
|||||
|
Delbaldo, 2004 (16) |
MAI |
Survie médiane |
30 |
4550 |
NS OR = 1,01 (0,85 -1,21) |
|
Azim, 2009 (17) |
MARSL (3ème
génération) |
Survie médiane |
6 |
1932 |
NS MR = 1,10 (0,91 -1,35 ; p =
0,059) |
|
Docétaxel en rattrapage : toutes les 3
semaines versus toutes les semaines |
|||||
|
Bria, 2006 (18) |
MAI |
Survie globale |
6 |
1018 |
NS RR = 1,06 (0,81 – 1,38) |
|
Di Maio 2007 (19) |
MADI |
Survie |
5 |
865 |
NS |
|
Entretien/consolidation |
|||||
|
Russo, 2009 (20) |
MAI (sujet âgé) |
Survie à 1 an |
4 |
1436 |
NS |
|
Lima, 2009 (21) |
MARSL |
Survie globale |
7 |
1559 |
NS |
|
Behera, 2012 (22) |
MAI (entretien par
monothérapie) |
Survie globale |
12 |
4286 |
S HR = 0,86 (0,82 - 0,92) |
|
Durée du traitement |
|||||
|
Soon, 2009 (23) |
MARSL |
Survie globale |
13 |
3027 |
S HR = 0,92 (0,85 – 0,99) en
faveur long traitement |
|
Zhang, 2011 (24) |
MARSL |
Survie globale |
8 |
3736 |
Switch : S HR = 0,85 (0,79 – 0,92) en
faveur traitement switch Continue : NS HR = 0,88 (0,74 – 1,04) en
faveur traitement continu |
|
Rattrapage |
|||||
|
Tassinari, 2009 (25) |
MARSL |
Survie à 1 an |
|
|
|
|
Traitement vs placebo |
3 |
2627 |
S OR = 0,74 (0,56 – 0,97) |
||
|
Docétaxel vs autre |
11 |
5952 |
NS OR = 0,92 (0,80 – 1,06) |
||
|
2ème versus 3ème génération |
|||||
|
Grossi, 2009 (26) |
MAI |
RO |
45 |
11231 |
NS |
|
Agents biologiques : chimiothérapie avec ou
sans l’agent |
|||||
|
Lin, 2010 (27) |
MARL |
Survie globale |
4 |
2018 |
S HR = 0,87 (0,79 – 0,96) en
faveur cétuximab |
|
Soria, 2013 (28) I |
MARL |
Survie globale |
4 |
2194 |
S HR = 0,90 (0,81 – 0,99) en
faveur bévacuzimab |
|
Paclitaxel en induction : toutes les 3
semaines vs hebdomadaire |
|||||
|
Gao, 2012 (29) |
MAI |
Survie globale |
5 |
940 |
NS |
(1) Donnadieu N, Paesmans M, Sculier JP. Chimiothérapie des cancers bronchiques non à petites cellules. Méta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir 1991;8(2):197-204.
(2) Sculier JP, Ghisdal L, Berghmans T, Branle F, Lafitte JJ, Vallot F, et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer 2001 May 4;84(9):1150-5.
(3) Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005 Jan;47(1):69-80.
(4) Sanchez LB, Penuelas S, I, Guillen GF. Docetaxel en combinacion con cisplatino para el tratamiento en primera linea del cancer del pulmon no microcitico metastasico o localmente avanzado : metaanalisis de ensayos clinicos aleatorizados y controlados. Med Clin (Barc ) 2004 Mar 6;122(8):281-7.
(5) Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007 Oct;2(10):939-46.
(6) Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009 Sep;65(3):339-44.
(7) Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004 Oct 1;22(19):3852-9.
(8) Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007 Jun 6;99(11):847-57.
(9) Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007 Sep;57(3):348-58.
(10) Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 2004 Dec;15(12):1782-9.
(11) Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008 Jan;59(1):1-11.
(12) D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature. J Clin Oncol 2005 Feb 22.
(13) Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006 Mar;51(3):335-45.
(14) Marino P, Preatoni A, Cantoni A, Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995 Aug;13(1):1-12.
(15) Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998 Jan 1;82(1):116-26.
(16) Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004 Jul 28;292(4):470-84.
(17) Azim HA, Jr., Elattar I, Loberiza FR, Jr., Azim H, Mok T, Ganti AK. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer 2009 May;64(2):194-8.
(18) Bria E, Cuppone F, Ciccarese M, Nistico C, Facciolo F, Milella M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006 Dec;32(8):583-7.
(19) Di Maio M., Perrone F, Chiodini P, Gallo C, Camps C, Schuette W, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007 Apr 10;25(11):1377-82.
(20) Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 2009 May 1;115(9):1924-31.
(21) Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009 Mar;45(4):601-7.
(22) Mauguen A, Le PC, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012 Aug 1;30(22):2788-97.
(23) Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009 Jul 10;27(20):3277-83.
(24) Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011 Jul;140(1):117-26.
(25) Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009 Jun;135(6):1596-609.
(26) Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009 May;14(5):497-510.
(27) Lin H, Jiang J, Liang X, Zhou X, Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010 Oct;70(1):57-62.
(28) Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013 Jan;24(1):20-30.
(29) Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012 Jun;76(3):380-6.